TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
TRINITY BIOTECH PLC
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 30, 2026
$8.19+0.16 (+1.99%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$21.51 (−72.43%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
TRINITY BIOTECH PLC grew revenue 8.3% to $61.56M over fiscal 2024. Free cash flow was -$4.60M.
Revenue
$61.56M
+8.3% vs. a year earlier
Operating income
-$21.17M
FY2024
Free cash flow
-$4.60M
FY2024
Key statistics
Valuation at the latest close; fundamentals over fiscal 2024, balances at Dec 31, 2024
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $61.56M
- Net income
- -$31.79M
- Free cash flow
- -$4.60M
Eleven years at a glance
Fiscal years 2014 to 2024, USD
Revenue
$61.56M+8.3% YoY
Gross profit
$21.44M+10.2% YoY
Operating income
-$21.17M
Net income
-$31.79M
Free cash flow
-$4.60M
Reported period